Back to Search Start Over

The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma

Authors :
Andrew W. Hahn
Justin Lebenthal
Giannicola Genovese
Kanishka Sircar
Nizar M. Tannir
Pavlos Msaouel
Source :
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100640- (2022)
Publication Year :
2022
Publisher :
Elsevier, 2022.

Abstract

Dedifferentiation in renal cell carcinoma (RCC), either sarcomatoid or rhabdoid, is an infrequent event that may occur heterogeneously in the setting of any RCC histology and is associated with poor outcomes. Sarcomatoid dedifferentiation is associated with inferior survival with angiogenesis targeted therapy and infrequent responses to cytotoxic chemotherapy. However, immune checkpoint therapy has significantly improved outcomes for patients with sarcomatoid dedifferentiation. Biologically, sarcomatoid dedifferentiation has increased programmed death-ligand 1 (PD-L1) expression and an inflamed tumor microenvironment, in addition to other distinct molecular alterations. Less is known about rhabdoid dedifferentiation from either a clinical, biological, or therapeutic perspective. In this focused review, we will discuss the prognostic implications, outcomes with systemic therapy, and underlying biology in RCC with either sarcomatoid or rhabdoid dedifferentiation present.

Details

Language :
English
ISSN :
24682942
Volume :
33
Issue :
100640-
Database :
Directory of Open Access Journals
Journal :
Cancer Treatment and Research Communications
Publication Type :
Academic Journal
Accession number :
edsdoj.7b57c73b221438ca018feb03373a2d4
Document Type :
article
Full Text :
https://doi.org/10.1016/j.ctarc.2022.100640